PATH | VRL
Menu

Efficacy of Fewer Than Three Doses of an HPV-16/18 AS04-Adjuvanted Vaccine: Combined Analysis of Data From the Costa Rica Vaccine and PATRICIA Trials

This article, published in The Lancet Oncology, reports on a study to evaluate the efficacy of fewer than the recommended three doses of human papillomavirus (HPV)-16/18 vaccine four years after vaccination. The authors found that one and two doses of the HPV-16/18 vaccine seem to protect against cervical HPV-16/18 infections with similar levels of protection as that provided by the three-dose schedule.

Author: Kreimer AR, Struyf F, Del Rosario-Raymundo MR, et al.

Published: 2015

» Visit web page (English)

(Located at www.thelancet.com)

Citation: Kreimer AR, Struyf F, Del Rosario-Raymundo MR, et al. Efficacy of Fewer Than Three Doses of an HPV-16/18 AS04-Adjuvanted Vaccine: Combined Analysis of Data From the Costa Rica Vaccine and PATRICIA Trials. The Lancet Oncology. 2015;16(7):775-786.

Resource types: Peer-reviewed journal

Diseases/vaccines: Human papillomavirus (HPV)

Topics: Vaccine safety and performance, Disease/vaccine specific information

Regions: Latin America and the Caribbean